Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo! News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix … Continue reading →

Geneva, Switzerland, 4 September 2013 - Addex Therapeutics (ADXN.SW), a leading company pioneering allosteric modulation-based drug discovery and development announced today additional positive preclinical data for its mGlu5 negative allosteric modulator (NAM) oral small molecule, dipraglurant, in a validated model for primary generalized torsion dystonia 1 (DYT1), a common and severe genetic form of dystonia, caused by a mutation in the TOR1A gene encoding the torsin A protein. In the study, that is part of an ongoing collaboration with Professor Antonio Pisani, University of Rome Tor Vergata and Fondazione Santa Lucia, chronic treatment with dipraglurant (50 mg/kg i.p. for 8 days) partially restored long-term depression and synaptic de-potentiation which are impaired in the DYT1 mutant mice over expressing the human mutant TOR1A gene. These data together with previously reported results obtained with dipraglurant in in vitro and in in vivo preclinical behavioral models, as well as observations made in the Phase 2a study of dipraglurant in Parkinson`s disease patients, further support the hypothesis that inhibition of mGlu5 could be beneficial in counteracting the abnormal electrophysiological function observed in dystonia. In keeping with the Company`s rare disease development strategy, Addex plans to initiate a Phase 2a study with dipraglurant in a … Continue reading →

Parkinson's Australia says it is disappointed a study with the potential to help patients may not have actually taken place. The organisation gave the University of Queensland a grant of $20,000 after positive study findings into the treatment were published. on Tuesday saying an internal investigation had revealed a study by a former staff member using a technique called Transcranial Magnetic Stimulation may not have been carried out. Parkinson's Australia's John Bird said the revelations are unfortunate as patients are keen to find a cure and ease the pain and discomfort of the illness. "We are obviously disappointed," Mr Bird said. The grant money has since been returned. Professor Bruce Murdoch, a former staff member from the university's Centre for Neurogenic Communication Disorders Research, was one of the authors of the article. The ABC has learnt other research by Professor Murdoch is now being reviewed. Professor Murdoch retired six weeks ago and his profile has been removed from the university's web site. A spokesman for the Stroke Foundation said it asked the university to look into research done by Professor Murdoch with Stroke Foundation money. Continued here: Parkinson's Australia disappointed research may not have been carried out by university researchers … Continue reading →

Public release date: 3-Sep-2013 [ | E-mail | Share ] Contact: Amy Pullan a.l.pullan@sheffield.ac.uk 01-142-229-859 University of Sheffield New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind. Experts from the world leading Sheffield Institute for Translational Neuroscience (SITraN) conducted a large scale drugs trial in the lab using skin cells from people with this progressive neurological condition which affects one in every 500 people in the UK. The researchers tested over 2,000 compounds to find out which ones could make faulty mitochondria work normally again. Mitochondria act as the power generators in all cells of our body, including the brain. Malfunctioning mitochondria are one of the main reasons why brain cells die in Parkinson's. One of the promising medications identified though the research is a synthetic drug called ursodeoxycholic acid (UDCA). This licenced drug has been in clinical use for several decades to treat certain forms of liver disease which means that researchers will be able to immediately start a clinical trial to test its safety and tolerability in people with Parkinson's. This … Continue reading →